1. Home
  2. VERO vs CDT Comparison

VERO vs CDT Comparison

Compare VERO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Venus Concept Inc.

VERO

Venus Concept Inc.

HOLD

Current Price

$1.14

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.10

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERO
CDT
Founded
N/A
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VERO
CDT
Price
$1.14
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.7M
1.2M
Earning Date
11-13-2025
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,876,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.91
52 Week High
$14.50
$384.00

Technical Indicators

Market Signals
Indicator
VERO
CDT
Relative Strength Index (RSI) 44.93 40.54
Support Level $1.24 $0.91
Resistance Level $1.44 $1.18
Average True Range (ATR) 0.30 0.12
MACD -0.11 0.01
Stochastic Oscillator 1.88 40.77

Price Performance

Historical Comparison
VERO
CDT

About VERO Venus Concept Inc.

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: